Attention-deficit/Hyperactivity Disorder (ADHD) Pipeline Insights, 2023 | Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies

April 25 15:58 2023
Attention-deficit/Hyperactivity Disorder (ADHD) Pipeline Insights, 2023 | Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 20+ key pharma and biotech companies are working on 22+ pipeline drugs in the Attention-deficit/Hyperactivity Disorder (ADHD) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Attention-deficit/Hyperactivity Disorder (ADHD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Attention-deficit/Hyperactivity Disorder Market. 

The Attention-deficit/Hyperactivity Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Attention-deficitHyperactivity Disorder (ADHD) Pipeline Analysis

Attention-deficit/Hyperactivity Disorder (ADHD) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Attention-deficit/Hyperactivity Disorder and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Attention-deficit/Hyperactivity Disorder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Attention Deficit Hyperactivity Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Attention-deficit/Hyperactivity Disorder Therapeutic Segment @

Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Landscape

There are approx. 20+ key companies developing therapies for Attention Deficit Hyperactivity Disorder. Currently, Otsuka Pharmaceutical is leading the therapeutics market with its Attention Deficit Hyperactivity Disorder drug candidates in the most advanced stage of clinical development.

The Leading Players in the Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market Include:

  • 3Z ehf Pharmaceuticals

  • ABVC BioPharma

  • AgoneX Biopharmaceuticals

  • Arbor Pharmaceuticals

  • BioLite, Inc.

  • Cennerv Pharma

  • Cingulate

  • Curemark

  • Ensysce Biosciences

  • EnvisionRx

  • INVENT Pharmaceuticals

  • KemPharm

  • Materia Medica Holding

  • NeuroNascent, Inc.

  • NLS Pharmaceutics Ltd

  • Otsuka Pharmaceutical

  • RespireRx Phamaceuticals

  • Supernus Pharmaceuticals

  • Tris Pharma, Inc.

And Many Others

Attention Deficit Hyperactivity Disorder Emerging and Marketed Drugs Covered in the Report Include:

  • PDC-142: BioLite, Inc.

  • Dasotraline: Sunovion

  • ORADUR-Methylphenidate: Orient Pharma

  • Centanafadine: Otsuka Pharmaceutical

  • SHP465: Shire

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Attention-deficit/Hyperactivity Disorder Current Treatment Patterns

4. Attention-deficit/Hyperactivity Disorder – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Attention-deficit/Hyperactivity Disorder Late Stage Products (Phase-III)

7. Attention-deficit/Hyperactivity Disorder Mid-Stage Products (Phase-II)

8. Attention-deficit/Hyperactivity Disorder Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Attention-deficit/Hyperactivity Disorder Discontinued Products

13. Attention-deficit/Hyperactivity Disorder Product Profiles

14. Key Companies in the Attention-deficit/Hyperactivity Disorder Market

15. Key Products in the Attention-deficit/Hyperactivity Disorder Therapeutics Segment

16. Dormant and Discontinued Products

17. Attention-deficit/Hyperactivity Disorder Unmet Needs

18. Attention-deficit/Hyperactivity Disorder Future Perspectives

19. Attention-deficit/Hyperactivity Disorder Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic healthcare market today @ Healthcare Partner Identification Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States